| Application: | 35273, Myeloproliferative neoplasms and clonal haematopoiesis |
| Title: | Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking |
| Size: | 570 B |
| Archived: | 29 Jul 2021 |
| Stability: | Complete |
| Personal: | No individual-level data |
Return 3685
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Notes
We sought to determine the significance of myeloid clonal hematopoiesis (CH) in the UK Biobank cohort (n = 502,524, median age = 58 years). Utilizing SNP array (n = 486,941) and whole exome sequencing data (n = 49,956), we identified 1166 participants with myeloid CH, defined by myeloid-associated mosaic chromosome abnormalities (mCA) and/or likely somatic driver mutations in DNMT3A, TET2, ASXL1, JAK2, SRSF2, or PPM1D. Myeloid CH increased by 1.1-fold per annum (myeloid mCA, P = 1.57 10-38; driver mutations, P = 5.89 10-47). Genome-wide association analysis identified two distinct signals within TERT that predisposed to myeloid CH, plus a weaker signal corresponding to the JAK2 46/1 haplotype. Specific subtypes of myeloid CH were associated with several blood features and clinical phenotypes, including TET2 mutations and chronic obstructive pulmonary disease. Smoking history was significantly associated with myeloid CH: 53% of myeloid CH cases were smokers compared to 44% of controls (P = 3.38 10-6), a difference principally due to current (OR = 1.10; P = 6.14 10-6) rather than past smoking (P = 0.08). Breakdown of CH by specific mutation type revealed that ASXL1 loss of function mutations were most strongly associated with current smoking status (OR = 1.07; P = 1.92 10-5), and the only abnormality associated with past smoking (OR = 1.04; P = 0.0026). We suggest that the inflammatory environment induced by smoking may promote the outgrowth of ASXL1-mutant clones.Application 35273
Myeloproliferative neoplasms and clonal haematopoiesis
We aim to (i) identify common genetic variation that predisposes to chronic myeloproliferative neoplasms (a type of blood cancer) and (ii) understand the relationship between age-related clonal haematopoiesis and the development of a myeloproliferative phenotype. This study will improve our understanding of genetic factors that contribute to the onset and severity of myeloproliferative neoplasms. We anticipate that our findings will improve methods to diagnose and stage these disorders, thus providing a framework for more personalised management. We will perform a genome wide association study by comparing genetic variation in patients with chronic myeloproliferative neoplasms (cases) and the Biobank population (controls). In addition we will analyse the Biobank population for evidence of somatically acquired clonal abnormalities, and relate this information to constitutional genetic factors as well as any available information on blood counts.
| Lead investigator: | Professor Nicholas Cross |
| Lead institution: | University of Southampton |
1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 3686 | Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking | Dawoud AAZ et al. | 2020 | Leukemia |
Enabling scientific discoveries that improve human health